Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy
Benton et al. identify binders against common mutant KRAS neoantigens and create peptide-centric CAR-T cells (NeoCARs). NeoCARs demonstrate a robust anti-tumor response against cancer cells expressing mutant KRAS peptides by MHC, both in vitro and in vivo. Inducible cytokine release and TCR deletion further enhance the therapeutic index.